早期联合药物干预治疗生殖器疱疹疗效评价

Effect of combined medication intervention on early genital herpes

目的:探讨早期匹多莫德联合伐昔洛韦干预治疗生殖器疱疹的临床疗效。方法:将86例生殖器疱疹患者随机分为早期干预组和对照组,每组43例。早期干预组给予口服匹多莫德联合伐昔洛韦进行早期干预治疗,对照组只给予口服伐昔洛韦治疗。两组患者同时治疗半个月左右,观察两组患者临床疗效。主要观察患者的皮损消退时间及皮损积分。结果:早期干预组的患者皮损消退时间短于对照组,与对照组比较差异无明显统计学意义(P<0.05),早期干预组的皮损积分值低于对照组,两组比较差异有统计学意义(P<0.05)。结论:匹多莫德联合伐昔洛韦早期干预治疗生殖器疱疹疗效显著,患者耐受性较好,值得在临床推广运用。

Objectives： To evaluate the intervention effect of Pidotimod combined with Valaciclovir on early genital herpes. Methods： 86 patients with genital herpes were randomly divided into the early intervention group and the control group, with 43 cases in each group. The patients in the early intervention group were treated with Pidotimod combined with Valaciclovir, and those in the control group were treated with Valaciclovir only. The clinical efficacy was evaluated ＇after half a month. Results： The lesion - subsided time of early intervention group was shorter than that of the control group, with no significant difference （ P 〈 0. 05 ）. The lesion integral quantity of early intervention group was lower than that of the control group and the difference was sig- nificant. （ P 〈 0. 05 ）. Conclusions ： Pidotimod combined with Valaciclovir can be adopted in the early intervention of genital herpes and produced remarkable curative effect. The therapy can be widely used in clinical treatment.